drugset
drugset / Trial / NCT01190475

BGS649 Monotherapy in Moderate to Severe Endometriosis Patients

NCT01190475 ↗

Phase 2 Completed 6 enrolled Mereo BioPharma Novartis · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will assess the safety and tolerability of BGS649 in women with moderate to severe endometriosis.

Timeline

Start
2010-07
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject BGS649 Unknown 0.1 mg —
Subject BGS649 Unknown 1 mg —

Indications

endometriosis